Cargando…
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expressed by other breast cancer subtypes. This pheno...
Autores principales: | Nasiri, Fatemeh, Kazemi, Mehrasa, Mirarefin, Seyed Mohamad Javad, Mahboubi Kancha, Maral, Ahmadi Najafabadi, Milad, Salem, Faeze, Dashti Shokoohi, Setareh, Evazi Bakhshi, Sahar, Safarzadeh Kozani, Pouya, Safarzadeh Kozani, Pooria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722775/ https://www.ncbi.nlm.nih.gov/pubmed/36483567 http://dx.doi.org/10.3389/fimmu.2022.1018786 |
Ejemplares similares
-
Nanobody-based CAR-T cells for cancer immunotherapy
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022) -
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022) -
Novel antigens of CAR T cell therapy: New roads; old destination
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021) -
CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2021) -
Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2021)